X-linked lymphoproliferative disease (XLP) and IL-2-inducible T cell kinase (ITK) deficiency are rare immunodeficiencies with a spectrum of clinical manifestations. Although there are no official guidelines for allogeneic hematopoietic stem cell transplantation (HSCT) in these patients, previous reports have shown that reduced intensity conditioning regimens provide successful engraftment with limited toxicity. Here, we report on three children with XLP and one with ITK deficiency, who underwent successful HSCT using a rituximab containing conditioning regimen, and review the current literature.
Keywords: Epstein Barr virus; ITK deficiency; Primary immunodeficiency; Rituximab; Stem cell transplantation; X-linked lymphoproliferative.
Copyright © 2014 Elsevier Inc. All rights reserved.